Alzheimer’s sleep restored by two hours in breakthrough study

Show summary Hide summary

• Why immune cells, not just plaques, are waking the brain
• How the experiment proved microglia drive sleep loss
  • Mouse models and targeted removal of microglia
  • Measuring sleep and brain activity
• Unexpected pattern: early immune response sets a lasting ceiling
• Restoring more than two hours of sleep in affected mice
• EEG signals as a practical biomarker for Alzheimer’s-related sleep change
• Translating the findings: calm microglia without erasing them
• Funding, authorship and next steps for research

Imagine a home sprinkler system that floods the entire house when a small kitchen blaze ignites. Designed to protect, it ends up doing more harm than the original fire. Scientists now say a similar overreaction happens in Alzheimer’s disease—where the brain’s immune cells go into overdrive and unintentionally disrupt sleep.

Researchers at the University of Kentucky report a breakthrough: by dialing down those immune cells in mice, they restored more than two hours of lost sleep each night. The findings point to a fresh angle for diagnosing and treating sleep disturbances tied to Alzheimer’s, with implications for memory, cognition, and everyday quality of life.

Why immune cells, not just plaques, are waking the brain

For years, amyloid plaques—sticky protein deposits that accumulate in Alzheimer’s—were blamed for the sleep troubles common in the disease. The UK team took a different tack and tracked how the brain’s resident immune cells, called microglia, react to those plaques. Their data suggest the microglial response, rather than the plaques themselves, is the main force behind the sleep disruption.

Lead investigator Shannon L. Macauley and colleague Nicholas J. Constantino argue that when microglia detect plaques they trigger a widespread inflammatory reaction. That immune “alarm” seems to keep the brain in a heightened, wakeful state, interrupting the cycles the brain uses to repair and consolidate memory.

How the experiment proved microglia drive sleep loss

Mouse models and targeted removal of microglia

The team compared two groups of mice: one engineered to develop amyloid plaques and another with normal aging. They examined animals at two stages—when plaques first appear and later during advanced pathology—so they could untangle disease effects from typical aging.

To test causality, researchers used the drug Pexidartinib (PLX3397), a molecule known to block survival signaling in microglia. Fed to mice for two weeks, the drug temporarily eliminated roughly 87% of microglia, allowing investigators to see what happened to sleep when the immune response was suppressed.

Measuring sleep and brain activity

Rather than rely on observational measures alone, the study used high-resolution brain recordings and algorithms to parse electrical signals. Scientists separated rhythmic brain waves from background electrical noise to determine whether the brain’s “engine” stayed active during rest.

• Electrophysiological monitoring distinguished wakefulness, non-REM (NREM) restorative sleep, and REM dreaming sleep.
• Analytic tools quantified changes in both periodic (oscillatory) and aperiodic (background) activity, offering precise signatures of sleep disruptions.

Unexpected pattern: early immune response sets a lasting ceiling

Contrary to the idea that sleep problems worsen steadily as plaques accumulate, the researchers observed a plateau. Sleep disruption emerged early, around the time plaques first formed, and did not grow proportionally with later, heavier plaque loads. The implication: the initial microglial reaction creates a lasting disturbance that further plaque accumulation does not significantly worsen.

These findings differentiate normal aging from disease-driven change: while healthy aging tends to reduce REM sleep, the microglial-driven process in Alzheimer’s selectively erodes NREM restorative sleep—the stage crucial for clearing metabolic waste, repairing neural tissue, and strengthening learning.

Restoring more than two hours of sleep in affected mice

When microglia were depleted by PLX3397, mice with amyloid pathology gained back a substantial portion of lost sleep. Key outcomes included:

• More than two extra hours of sleep per 24-hour period compared with untreated Alzheimer-model mice.
• Longer, more consolidated NREM sleep bouts, giving the brain greater opportunity to transition into REM cycles important for memory formation.
• No immediate reduction in amyloid plaque burden—suggesting the sleep gains were driven by lowering inflammation rather than removing plaques.

That separation—improved sleep without changing plaque levels—supports the idea that inflammation-driven sleep loss may be a reversible, targetable component of the disease.

EEG signals as a practical biomarker for Alzheimer’s-related sleep change

The investigators identified distinct electrical signatures that differentiate Alzheimer’s-associated sleep disruption from normal aging. Because the patterns can be picked up with EEG, the study highlights a potential path for low-cost, longitudinal monitoring in real-world settings.

• Portable EEG systems could enable at-home tracking of sleep and brain activity, providing an early-warning signal of disease-related changes.
• Such monitoring might reduce the need for immediate invasive or expensive tests and let community clinics screen patients locally.

Accessible EEG markers could therefore become a practical screening tool to flag risk or monitor progression, enabling earlier intervention and research participation.

Translating the findings: calm microglia without erasing them

Because microglia perform many essential roles, completely removing them is not a sustainable therapy for humans. Instead, Macauley’s lab is exploring ways to dial down their overactivity. The team is testing whether existing medications that alter cellular metabolism—such as metformin (a diabetes drug) or stiripentol (an anti-seizure medicine)—can reset microglial behavior and reduce the inflammatory signals that keep the brain awake.

Possible therapeutic strategies under investigation include:

1. Metabolic modulation to shift how microglia use fuel and respond to amyloid.
2. Pharmacologic “reprogramming” that reduces inflammatory signaling without deleting microglia.
3. Noninvasive monitoring with portable EEG to measure treatment impact on sleep over time.

By aiming to quiet the immune overreaction rather than eliminate a cell population, researchers hope to restore restorative sleep years before severe memory loss emerges, improving cognition, attention, and daily functioning.

Funding, authorship and next steps for research

The work, published in Alzheimer’s & Dementia, was led by Shannon L. Macauley with first author Nicholas J. Constantino, and received support from the NIH, the Cure Alzheimer’s Fund, and The CART Fund. The team’s next studies will probe safe approaches to temper microglial activity in humans and validate EEG markers in clinical populations.

You might also like:

• DMT, the spirit molecule, protects brain from stroke in mice, study finds
• Vitamin K may form basis for new treatment for neurodegenerative diseases
• Alzheimer’s antibody from camels and alpacas shows promise as a treatment
• MS: high-altitude yak gene protects and repairs myelin in early study
• Breast cancer risk lower after childbirth and breastfeeding, new study finds